Researchers Face Off Over Incretin Risk

(MedPage Today) -- As concerns escalate over the potential risks of glucagon-like peptide-1 (GLP-1)-based therapies, a diabetes journal hosted a point-counterpoint debate between the researchers who have been the leading voices on each side of the issue.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news